Gupta Rishi
Insider CIK 1537370 · CCXI Director · DMTX Director, 10% owner · VRNA Director · ELVN Director, 10% owner · TSBX Director, 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ELVN Enliven Therapeutics, Inc. | A Award deriv | 2026-02-12 | 2026-02-17 | 33,989 | — | $0 | 33,989 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award deriv | 2026-02-12 | 2026-02-17 | 1,580 | — | $0 | 1,580 | SEC↗ |
| TSBX Turnstone Biologics Corp. | U Tender | 2025-08-08 | 2025-08-08 | 3,099,265 | — | $0 | 0 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award deriv | 2025-02-06 | 2025-02-10 | 20,491 | — | $0 | 20,491 | SEC↗ |
| TSBX Turnstone Biologics Corp. | A Award deriv | 2024-06-03 | 2024-07-02 | 12,770 | — | $0 | 12,770 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2024-05-16 | 2024-05-20 | 1,000,000 | $22.14 | $22.14M | 7,663,349 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2024-05-16 | 2024-05-20 | 33,300 | $22.14 | $737.3K | 254,814 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award deriv | 2024-02-13 | 2024-02-15 | 16,835 | — | $0 | 16,835 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award deriv | 2024-02-13 | 2024-02-20 | 23,364 | — | $0 | 23,364 | SEC↗ |
| TSBX Turnstone Biologics Corp. | A Award deriv | 2023-10-16 | 2023-10-17 | 25,540 | — | $0 | 25,540 | SEC↗ |
| TSBX Turnstone Biologics Corp. | C Conversion deriv | 2023-07-20 | 2023-07-24 | 937,372 | — | $0 | 0 | SEC↗ |
| TSBX Turnstone Biologics Corp. | C Conversion deriv | 2023-07-20 | 2023-07-24 | 229,158 | — | $0 | 0 | SEC↗ |
| TSBX Turnstone Biologics Corp. | C Conversion deriv | 2023-07-20 | 2023-07-24 | 266,240 | — | $0 | 0 | SEC↗ |
| TSBX Turnstone Biologics Corp. | C Conversion deriv | 2023-07-20 | 2023-07-24 | 1,249,829 | — | $0 | 0 | SEC↗ |
| TSBX Turnstone Biologics Corp. | P Buy | 2023-07-20 | 2023-07-24 | 416,666 | $12.00 | $5.00M | 3,099,265 | SEC↗ |
| TSBX Turnstone Biologics Corp. | C Conversion | 2023-07-20 | 2023-07-24 | 2,682,599 | — | $0 | 2,682,599 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2023-05-17 | 2023-05-19 | 2,125 | — | $0 | 0 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2023-05-17 | 2023-05-19 | 2,125 | $4.28 | $9.1K | 8,663,349 | SEC↗ |
| VRNA Verona Pharma plc | S Sale | 2023-05-15 | 2023-05-15 | 345,313 | $20.00 | $6.91M | 3,777,778 | SEC↗ |
| VRNA Verona Pharma plc | S Sale | 2023-05-15 | 2023-05-15 | 14,400 | $21.96 | $316.2K | 4,123,091 | SEC↗ |
| VRNA Verona Pharma plc | S Sale | 2023-05-12 | 2023-05-15 | 43,200 | $21.64 | $934.8K | 4,137,491 | SEC↗ |
| VRNA Verona Pharma plc | S Sale | 2023-05-11 | 2023-05-15 | 80,000 | $22.26 | $1.78M | 4,180,691 | SEC↗ |
| VRNA Verona Pharma plc | A Award deriv | 2023-04-28 | 2023-04-28 | 96,000 | — | $0 | 96,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award deriv | 2023-02-23 | 2023-04-06 | 27,567 | — | $0 | 27,567 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award | 2023-02-23 | 2023-02-27 | 288,114 | — | $0 | 288,114 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award | 2023-02-23 | 2023-02-27 | 7,611,458 | — | $0 | 7,611,458 | SEC↗ |
| VRNA Verona Pharma plc | S Sale | 2022-12-23 | 2022-12-27 | 1,116,048 | $23.23 | $25.93M | 34,178,520 | SEC↗ |
| VRNA Verona Pharma plc | S Sale | 2022-12-23 | 2022-12-27 | 961,328 | $22.27 | $21.41M | 35,294,568 | SEC↗ |
| VRNA Verona Pharma plc | S Sale | 2022-12-23 | 2022-12-27 | 92,992 | $24.11 | $2.24M | 34,085,528 | SEC↗ |
| VRNA Verona Pharma plc | S Sale | 2022-12-22 | 2022-12-27 | 3,284,800 | $21.71 | $71.31M | 36,940,592 | SEC↗ |
| VRNA Verona Pharma plc | S Sale | 2022-12-22 | 2022-12-27 | 684,696 | $22.07 | $15.11M | 36,255,896 | SEC↗ |
| VRNA Verona Pharma plc | A Award deriv | 2022-04-28 | 2022-04-29 | 200,000 | — | $0 | 200,000 | SEC↗ |
| VRNA Verona Pharma plc | A Award deriv | 2021-08-09 | 2021-08-10 | 64,000 | — | $0 | 64,000 | SEC↗ |
| DMTX Dimension Therapeutics, In | A Award deriv | 2016-05-19 | 2016-05-23 | 32,069 | — | $0 | 32,069 | SEC↗ |
| DMTX Dimension Therapeutics, In | C Conversion deriv | 2015-10-27 | 2015-10-29 | 5,692,874 | — | $0 | 0 | SEC↗ |
| DMTX Dimension Therapeutics, In | C Conversion deriv | 2015-10-27 | 2015-10-29 | 9,500,000 | — | $0 | 0 | SEC↗ |
| DMTX Dimension Therapeutics, In | C Conversion | 2015-10-27 | 2015-10-29 | 1,947,613 | — | $0 | 5,197,698 | SEC↗ |
| DMTX Dimension Therapeutics, In | P Buy | 2015-10-27 | 2015-10-29 | 200,000 | $13.00 | $2.60M | 5,397,698 | SEC↗ |
| DMTX Dimension Therapeutics, In | C Conversion | 2015-10-27 | 2015-10-29 | 3,250,085 | — | $0 | 3,250,085 | SEC↗ |
| CCXI ChemoCentryx, Inc. | A Award deriv | 2012-06-22 | 2012-06-26 | 12,500 | — | $0 | 12,500 | SEC↗ |